In the realm of bullish stocks, EVgo (EVGO) experienced a significant increase of 60.81%, continuing a two-day upward trend with a cumulative gain of 64.58% over this period. The positive momentum follows an upgrade by TD Cowen, which raised the company’s rating to “Buy” and increased the target price to $7.
Additionally, AMTD Digital (HKD) surged by 33.50%, marking a two-day increase of 63.13%. The optimistic earnings report from Constellation Brands inspired a rise in big stocks, including Constellation Energy, during pre-market trading on Thursday.
Meanwhile, Cartesian (RNAC) saw a three-day climb, rising 26.85% and achieving a total gain of 41.56%. This growth was driven by Cartesian Therapeutics receiving the FDA's rare pediatric disease designation for Descartes-08, intended for treating juvenile dermatomyositis.
Sagimet Biosciences (SGMT) increased by 21.18%, maintaining a three-day streak with a total gain of 48.74%. Sagimet, a strategic partner of Ascletis Pharma, received an FDA Breakthrough Therapy Designation for its treatment for fibrosis stage 2/3 NASH patients confirmed by liver biopsy.
Eton Pharmaceuticals (ETON) rose by 16.33%, securing a two-day increase of 16.92%. Eton Pharmaceuticals will acquire Increlex (mecasermin injection) from Ipsen. This acquisition aims to strengthen Eton's pediatric endocrinology portfolio.
Conversely, within the bearish stocks, Laser Photonics (LASE) declined by 26.15%, marking a three-day drop of 43.72%. The decline followed a bearish report released by Capybara Research.
Qifu Technology (QSG) fell by 17.40%. Despite a 33% stock price increase, Qifu Technology Limited's revenue remained stagnant.
AngioDynamics (ANGO) saw a decrease of 16.73%. The downturn was due to first-quarter revenues missing expectations, resulting in a drop in stock price.
NetEase Youdao (DAO) dropped by 13.78%. During trading hours, the online education sector weakened, with Youdao leading the decline.
NOVAGOLD RESOURCES (NG) decreased by 13.33%. The company reported an EPS of -$0.03, missing estimates by 1 cent, and confirmed its fiscal 2024 outlook. Post-market trading saw the stock fall 2.3%, aligning with a stable fiscal Q3 loss, as it focuses on advancing the Donlin Gold project.